iTRAQ-based proteomics profiling reveals increased metabolic activity and cellular cross-talk in angiogenic compared with invasive glioblastoma phenotype.
Malignant gliomas (glioblastoma multiforme) have a poor prognosis with an average patient survival under current treatment regimens ranging between 12 and 14 months. The tumors are characterized by rapid cell growth, extensive neovascularization, and diffuse cellular infiltration of normal brain structures. We have developed a human glioblastoma xenograft model in nude rats that is characterized by a highly infiltrative non-angiogenic phenotype. Upon serial transplantation this phenotype will develop into a highly angiogenic tumor. Thus, we have developed an animal model where we are able to establish two characteristic tumor phenotypes that define human glioblastoma (i.e. diffuse infiltration and high neovascularization). Here we aimed at identifying potential biomarkers expressed by the non-angiogenic and the angiogenic phenotypes and elucidating the molecular pathways involved in the switch from invasive to angiogenic growth. Focusing on membrane-associated proteins, we profiled protein expression during the progression from an invasive to an angiogenic phenotype by analyzing serially transplanted glioma xenografts in rats. Applying isobaric peptide tagging chemistry (iTRAQ) combined with two-dimensional LC and MALDI-TOF/TOF mass spectrometry, we were able to identify several thousand proteins in membrane-enriched fractions of which 1460 were extracted as quantifiable proteins (isoform- and species-specific and present in more than one sample). Known and novel candidate proteins were identified that characterize the switch from a non-angiogenic to a highly angiogenic phenotype. The robustness of the data was corroborated by extensive bioinformatics analysis and by validation of selected proteins on tissue microarrays from xenograft and clinical gliomas. The data point to enhanced intercellular cross-talk and metabolic activity adopted by tumor cells in the angiogenic compared with the non-angiogenic phenotype. In conclusion, we describe molecular profiles that reflect the change from an invasive to an angiogenic brain tumor phenotype. The identified proteins could be further exploited as biomarkers or therapeutic targets for malignant gliomas.
Rajcevic
Uros
U
Norlux Neuro-Oncology Laboratory, Department of Oncology, Centre de Recherche Public Santé (CRP-Santé), 84 Val Fleuri, L-1526 Luxembourg, Luxembourg.
Petersen
Kjell
K
Knol
Jaco C
JC
Loos
Maarten
M
Bougnaud
Sébastien
S
Klychnikov
Oleg
O
Li
Ka Wan
KW
Pham
Thang V
TV
Wang
Jian
J
Miletic
Hrvoje
H
Peng
Zhao
Z
Bjerkvig
Rolf
R
Jimenez
Connie R
CR
Niclou
Simone P
SP
D000369:Aged, 80 and over; D000818:Animals; D001706:Biopsy; D001932:Brain Neoplasms / Q000378:metabolism / Q000473:pathology*; D002853:Chromatography, Liquid / Q000379:methods; D005260:Female; D005909:Glioblastoma / Q000378:metabolism / Q000473:pathology*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009361:Neoplasm Invasiveness; D009368:Neoplasm Transplantation; D009389:Neovascularization, Pathologic; D020411:Oligonucleotide Array Sequence Analysis; D040901:Proteomics / Q000379:methods*; D051381:Rats; D011923:Rats, Nude; D019032:Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization
Curr Opin Mol Ther. 2008 Apr;10(2):116-23
18386223
Front Biosci (Landmark Ed). 2009 Jan 01;14:3292-303
19273274
Cell. 1996 Aug 9;86(3):353-64
8756718
Biochem Biophys Res Commun. 2005 Dec 2;337(4):1283-7
16236264
Immunol Res. 2006;35(1-2):151-62
17003517
Am J Pathol. 2007 May;170(5):1445-53
17456751
Acta Neuropathol. 2003 Jan;105(1):49-57
12471461
Oncol Res. 1994;6(12):561-7
7787249
Thromb Haemost. 2005 Feb;93(2):199-204
15711733
Nat Rev Neurosci. 2007 Aug;8(8):610-22
17643088
Cancer Res. 2003 Oct 15;63(20):6962-70
14583498
Proc Natl Acad Sci U S A. 1999 Mar 16;96(6):2907-12
10077610
Brain Pathol. 2005 Oct;15(4):311-7
16389943
Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10781-6
11535808
FEBS Lett. 2004 Aug 27;573(1-3):83-92
15327980
Int Rev Cytol. 2005;245:91-121
16125546
Curr Protoc Bioinformatics. 2008 Mar;Chapter 7:Unit 7.3
18428687
Proc Natl Acad Sci U S A. 2006 Oct 31;103(44):16466-71
17056721
J Proteome Res. 2005 May-Jun;4(3):725-33
15952719
J Clin Invest. 2004 Jan;113(1):38-48
14702107
Proteomics. 2007 Aug;7(16):3010-29
17654460
Bioinformatics. 2001 Apr;17(4):369-70
11301307
Cancer Res. 2006 Oct 15;66(20):9895-902
17047051
Expert Opin Biol Ther. 2008 Apr;8(4):541-53
18352856
NMR Biomed. 2008 Oct;21(8):830-8
18613001
Acta Neuropathol. 2007 Aug;114(2):97-109
17618441
J Natl Cancer Inst. 2007 Nov 7;99(21):1583-93
17971532
J Neurosurg. 1990 Mar;72(3):463-75
2406382
Glia. 2007 Dec;55(16):1630-7
17823964
Nat Biotechnol. 2003 May;21(5):508-10
12721575
Curr Pharm Des. 2007;13(35):3568-75
18220793
Cancer Res. 1990 Sep 15;50(18):6039-44
2393868
J Proteome Res. 2007 Aug;6(8):3127-33
17625814
Ernst Schering Res Found Workshop. 2003;(42):11-7
12664532
Nature. 2000 Sep 14;407(6801):249-57
11001068
Glia. 2006 May;53(7):723-32
16506224